Jörn Drappa
Director/Board Member bij ALPINE IMMUNE SCIENCES, INC.
Vermogen: - $ op 31-03-2024
Profiel
Jörn Drappa is the founder of Viela Bio, Inc. (founded in 2018), where he held the title of Chief Medical Officer and Head of Research & Development until 2021.
He is currently a Director at Alpine Immune Sciences, Inc. since 2022.
Dr. Drappa's former positions include Associate Director-Medical at Amgen, Inc. (2003-2006), Senior Director-Medical at Genentech, Inc. (2008-2011), Vice President-Clinical Development at Medimmune, Inc. (2011-2018), Executive Vice President-Research & Development at Horizon Therapeutics Plc (2021), and Chief Medical Officer at Ventyx Biosciences, Inc. (2021-2022).
Dr. Drappa received a doctorate from Universität zu Köln in 1991 and another doctorate from Weill Cornell Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
02-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Jörn Drappa
Bedrijven | Functie | Begin |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 18-07-2022 |
Eerdere bekende functies van Jörn Drappa
Bedrijven | Functie | Einde |
---|---|---|
VENTYX BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 05-05-2022 |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01-09-2021 |
VIELA BIO, INC. | Founder | 15-03-2021 |
Medimmune, Inc. | Chief Tech/Sci/R&D Officer | 01-02-2018 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01-05-2011 |
Opleiding van Jörn Drappa
Universität zu Köln | Doctorate Degree |
Weill Cornell Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AMGEN INC. | Health Technology |
VENTYX BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Medimmune, Inc. | Health Technology |
Alpine Immune Sciences, Inc. | |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |